Skip to main content
Miguel Chillón

Miguel Chillón

Universitat Autònoma de Barcelona

Life & Medical Sciences

Born in Barcelona in 1966. PhD in Genetics at Hospital Duran i Reynals and Universitat de Barcelona, 1994. National Award in Human Genetics by the Spanish Association of Human Genetics in 1995. HHMI postdoctoral fellow on Gene Therapy for Cystic Fibrosis, at the Internal Medicine Dept, University of Iowa, USA (1994-1997). EMBO fellow in Genethon III (Evry, France) (1997-1999) on Development of viral vectors for Gene Therapy. Postdoctoral fellow on Gene Therapy (2000-2001) at the Universitat Autònoma de Barcelona (UAB). ICREA Research Professor at the UAB since 2001. Director of the Vector Production Unit, a technological platform to produce viral vectors, since 2004. Assistant Professor of the Biochemistry and Molecular Biology Dept. at the UAB since 2005. Co-founder of two spin-off companies in biotechnology, NanoTherapix in 2009, and Kogenix Therapeutics in 2016. He has published more than 80 papers and generated 9 patents in viral vectors. 

Research interests

Medicine still has many challenges to solve especially on complex diseases where a large number of both, genetic and environmental factors, are involved. Among them, aging-associated diseases and rare disorders have attracted attention because there are no effective curative treatments for them. Some of these diseases affect the central nervous system, which in addition, is difficult to access and to manipulate with classical pharmacological treatments. To address these problems we have focused our research interests on three main objectives: (1) gene therapy strategies for diseases affecting the nervous system, such as rare neuromuscular and neurodegenerative disorders; (2) gene therapy strategies using chronokines for cognitive decline and dementia; and (3) development of more efficient and less immunogenic viral vectors.

Selected publications

– M Vogel-Gonzalez; M Tallo-Parra; V Herrera-Fernandez; G. Perez-Vilaro; M Chillon; X. Nogues; S Gomez-Zorrilla; I Lopez-Montesinos; I Arnau-Barres; ML Sorli-Redo; JP Horcajada; N Garcia-Giralt; J Pascual; J Diez; R Vicente; R Guerri-Fernandez. 2021, ‘Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection’, Nutrients, 13, 2, 562.

– C Grinan-Ferre; A Bellver-Sanchis; V Izquierdo; R Corpas; J Roig-Soriano; M Chillon; C Andres-Lacueva; M Somogyvari; C Soti; C Sanfeliu; M Pallas. 2021, ‘The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: From antioxidant to epigenetic therapy’, Ageing Research Reviews, 67, 101271.

– E Aubets; M Chillon; CJ Ciudad; V Noe. 2021, ‘PolyPurine Reverse Hoogsteen Hairpins Work as RNA Species for Gene Silencing’, International Journal Of Molecular Sciences, 22, 18, 10025.

– G Mòdol-Caballero, B García-Lareu, M Herrando-Grabulosa, S Verdés, R López-Vales, G Pagès, M Chillon, X Navarro, A Bosch.  “Specific expression of Glial-Derived Neurotrophic Factor in muscles as gene therapy strategy for Amyotrophic Lateral Sclerosis”. Neurotherapeutics: 18:1113-1126.

– TA Rubinstein, I Reuveni, A Hesin, AK Goldberg, H Olauson, TE Larsson, CR Abraham, E Zeldich, A Bosch, M Chillón, KS Hollander, AY Orbach, GW Vainer, I Wolf , and T Rubinek. “A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy”. Cancers, 13(24):6297.

ICREA Memoir 2021